Back to top
more

Moderna (MRNA)

(Delayed Data from NSDQ)

$25.24 USD

25.24
17,486,882

-0.21 (-0.83%)

Updated Sep 19, 2025 04:00 PM ET

After-Market: $25.28 +0.04 (0.16%) 5:38 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.64%
2Buy17.83%
3Hold9.69%
4Sell5.29%
5Strong Sell2.54%
S&P50011.29%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 40% (99 out of 245)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Should You Invest in the VanEck Biotech ETF (BBH)?

by Zacks Equity Research

Sector ETF report for BBH

Zacks Equity Research

Moderna (MRNA) Gains As Market Dips: What You Should Know

by Zacks Equity Research

Moderna (MRNA) closed at $216.06 in the latest trading session, marking a +0.39% move from the prior day.

Zacks Equity Research

Moderna (MRNA) Begins Dosing in Study on Vaccine Against EBV

by Zacks Equity Research

Moderna (MRNA) doses the first participant in a phase I study evaluating its Epstein-Barr virus vaccine candidate, mRNA-1189.

Zacks Equity Research

Pfizer and BioNTech to Make mRNA-Based Shingles Vaccine

by Zacks Equity Research

Pfizer (PFE) and BioNTech (BNTX) plan to develop an mRNA-based vaccine for shingles after witnessing success with their COVID-19 vaccine.

Zacks Equity Research

Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for IBB

Zacks Equity Research

Pfizer, BioNTech Booster Gets FDA Nod for 12 to 15-Year Olds

by Zacks Equity Research

FDA authorizes the booster shot of Pfizer (PFE) and BioNTech's (BNTX) COVID-19 vaccine for adolescents 12 through 15 years of age.

Zacks Equity Research

Novavax (NVAX) Further Delays FDA Filing for COVID-19 Vaccine

by Zacks Equity Research

Novavax's (NVAX) filing with the FDA seeking approval for emergency use authorization of its COVID-19 vaccine, NVX-CoV2373, gets further postponed to January 2022.

Zacks Equity Research

Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)?

by Zacks Equity Research

Sector ETF report for FBT

Zacks Equity Research

Moderna (MRNA) Gains As Market Dips: What You Should Know

by Zacks Equity Research

In the latest trading session, Moderna (MRNA) closed at $253.98, marking a +0.95% move from the previous day.

Zacks Equity Research

J&J (JNJ) COVID Booster Jab Shows Effectiveness Against Omicron

by Zacks Equity Research

Johnson & Johnson's (JNJ) COVID booster vaccine demonstrates 85% effectiveness against COVID-related hospitalization in South Africa, with Omicron becoming the dominant variant.

Zacks Equity Research

Should You Invest in the iShares Biotechnology ETF (IBB)?

by Zacks Equity Research

Sector ETF report for IBB

Zacks Equity Research

Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for FBT

Mark Vickery headshot

Santa Rally Takes a Breather Going into Mid-Week

by Mark Vickery

With only three more trading days before the end of 2021, we're seeing something we haven't for five years: the S&P outperforming the Nasdaq.

Sweta Killa headshot

5 Stocks That Have Powered the S&P 500 ETF in 2021

by Sweta Killa

The S&P 500 has been enjoying smooth trading this year with the benchmark reaching the 69th record close of the year.

Ekta Bagri headshot

3 Biotech Stocks Worth Adding to Your Portfolio Next Year

by Ekta Bagri

Here we present three biotech companies, which are likely to perform well in 2022, backed by strong fundamentals.

Zacks Equity Research

Moderna (MRNA) Down as Pfizer Paxlovid EUA May Fuel Competition

by Zacks Equity Research

Moderna's (MRNA) COVID-19 vaccine may face stiffer competition following the FDA's emergency approval of an oral COVID-19 pill, Pfizer's Paxlovid, which may result in lower sales.

Zacks Equity Research

Novavax (NVAX) COVID-19 Booster Jab Effective Against Omicron

by Zacks Equity Research

Novavax's (NVAX) protein-based COVID vaccine shows a cross-reactivity response against the Omicron variant. It will also start clinical studies on an Omicron-specific vaccine in first-quarter 2022.

Ekta Bagri headshot

5 Biotech Stocks That More Than Doubled This Year

by Ekta Bagri

The biotech sector has been in focus through 2021 as vaccine makers like Moderna (MRNA) BioNTech (BNTX), and other companies like Dynavax (DVAX), Prothena (PRTA) and Intellia (NTLA) put up an exemplary performance.

Mark Vickery headshot

Markets Stay Up on Omicron News; Home Sales in Focus

by Mark Vickery

Today and yesterday, we've begun to see an influx of reports about Omicron blowing through populations rapidly but rather benignly.

Zacks Equity Research

Novavax (NVAX) Commences COVID-19 Vaccine Booster Study

by Zacks Equity Research

Novavax (NVAX) initiates a phase III study to evaluate the booster dose of its COVID vaccine. WHO recommends administering the company's COVID vaccine booster to immunocompromised persons.

Zacks Equity Research

Novavax (NVAX) COVID Vaccine Gets EU Nod, 2nd Listing by WHO

by Zacks Equity Research

Novavax (NVAX) secures approval for its COVID vaccine in the European Union. Following EU approval, WHO grants second emergency use listing to the company's COVID vaccine.

Zacks Equity Research

Moderna (MRNA) COVID-19 Booster Jab Effective Against Omicron

by Zacks Equity Research

Data from a pseudovirus study demonstrated that the authorized booster dose of Moderna's (MRNA) COVID-19 vaccine significantly increases neutralizing antibody levels against the Omicron variant.

Zacks Equity Research

Stock Market News for Dec 21, 2021

by Zacks Equity Research

Benchmarks recorded a steep decline on Monday as investors worried about the fast-spreading omicron variant of COVID-19, raising doubts on the global economic outlook.

Sweta Killa headshot

Biotech ETFs That Outperformed Last Week

by Sweta Killa

Biotech ETFs was the biggest gainer last week.

Zacks Equity Research

Emergent (EBS) Begins Dosing in Study on Influenza Vaccine

by Zacks Equity Research

Emergent (EBS) initiates a phase I study evaluating EBS-UFV-001, the company's investigational universal influenza vaccine candidate.